-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only to read and refer to the latest post-mortem analysis of the hypoglycemic ceiling, taking into account efficacy and safetyIn
recent years, with the development of diagnosis and treatment concepts in the field of diabetes, the research of new hypoglycemic drugs has also been continuously updated, the 58th European Association for the
Study of Diabetes in September 2022 The (EASD) Annual Meeting was successfully held in Stockholm, Sweden, during which a large number of new research and progress
on diabetes treatment drugs were announced.
Among them, the research on the new diabetes treatment drug Tirzepatide is of particular interest
.
At the EASD annual meeting, a study on Tirzepatide to enable patients with type 2 diabetes mellitus (T2D) to reach their blood glucose goals faster [1], based on this study, the "medical community" invited Professor Tong Nanwei of West China Hospital of Sichuan University to further interpret and share, giving advice and inspiration
to the majority of endocrinology medical workers on the platform.
S.
Food and Drug Administration (FDA) for the treatment
of T2D 。 Tirzepatide is a single molecule that binds and activates both GIP receptors and GLP-1 receptors, both of which belong to incretinin and play an important role
in glucose and energy metabolism.
In addition to promoting insulin secretion, GLP-1 also has the effect of inhibiting glucagon secretion, but this inhibition is absent
in hypoglycemia.
In addition, GLP-1 can also slow gastric emptying, promote satiety, and reduce food intake [2].
At the same time, GIP has been shown to promote insulin secretion in a glucose-dependent manner and, in the physiological state, has been shown to have a stronger insulin secretion effect than GLP-1 [3,4].
As a new hypoglycemic drug, Tirzepatide has both GIP and GLP-1 receptor agonism, and has obvious advantages for the control of blood glucose and weight in T2D patients [5-9].
Professor Tong Nanwei further explained: "Previous SURPASS series clinical trials [5-9] have evaluated the efficacy and safety of Tirzepatide (5mg, 10mg and 15mg) as a monotherapy and a representative class of hypoglycemic drugs in combination with T2D
。 Active comparators in the study included semeglutide injection 1 mg, insulin degludecine, and insulin
glargine.
Overall, data from five global registration clinical trials showed that Tirzepatide significantly reduced glycated hemoglobin (HbA1c) and body weight
in all three dose groups in T2D subjects with different diabetic courses.
"
From the data that have been reported, in the SURPASS-2 study comparing the efficacy and safety of Tirzepatide and semeglutide 1 mg in T2D patients with poor glycemic control after metformin treatment, at week 40, Tirzepatide 5 mg, 10 mg and 15 mg groups HbA1c Compared with the baseline change and the proportion of patients with HbA1c < 7%, ≤ 6.
5%, and <b24><</b24> 5.
7%, were better than those in the semeglutide 1 mg group
.
In the SURPASS-3 study, the change from baseline in the Tirzepatide 5mg, 10 mg, and 15 mg groups compared to baseline and the proportion of patients with HbA1c < 7%, ≤ 6.
5%, and <b25><</b25> 5.
7% were also better than titrated doses of insulin degludec at week 52
。 Professor Nanwei Tong concluded: "The data from the SURPASS series of studies show that Tirzepatide can bring significant hypoglycemic and weight-loss benefits
to T2D patients.
”
This year EASD disclosed a post-hoc analysis of a SURPASS-2 and SURPASS-3 study [1] designed to evaluate glycemic control goals (HbA 1c<7%/HbA) with Tirzepatide compared to semeglutide 1 mg and a titrated dose of degludecin in T2D patients</b10> and (≥) of (
Note: TZP, Tirzepatide; HR, risk ratio
.
"Combined with the data characteristics of the study, from the aspect of lowering glucose, we can find that some existing treatment options, such as long-acting insulin therapy, cannot achieve glycemic control goals within 3 months, while Tirzepatide can achieve it
.
" From the perspective of weight loss, Tirzepatide lost more than 5% of weight, which has actually achieved the effect of weight-loss drugs, and in T2D patients, Tirzepatide lost weight significantly faster than semeglutide 1mg
.
For the risk of hypoglycemia, which patients are concerned about, Tirzepatide also performs well
.
Professor Tong Nanwei explained
.
UKPDS [10] has found that glycemic control is important in the metabolic management of diabetes, finding that every 1% decrease in HbA1c reduces the risk of all diabetes-related endpoints and diabetes-related death by 21% (P<0.
01)</b11>
"This article is only used to provide scientific information to medical and health professionals, and does not represent the position of the platform" Submission/reprint/business cooperation, please contact: pengsanmei@yxj.
org.
cn
recent years, with the development of diagnosis and treatment concepts in the field of diabetes, the research of new hypoglycemic drugs has also been continuously updated, the 58th European Association for the
Study of Diabetes in September 2022 The (EASD) Annual Meeting was successfully held in Stockholm, Sweden, during which a large number of new research and progress
on diabetes treatment drugs were announced.
Among them, the research on the new diabetes treatment drug Tirzepatide is of particular interest
.
At the EASD annual meeting, a study on Tirzepatide to enable patients with type 2 diabetes mellitus (T2D) to reach their blood glucose goals faster [1], based on this study, the "medical community" invited Professor Tong Nanwei of West China Hospital of Sichuan University to further interpret and share, giving advice and inspiration
to the majority of endocrinology medical workers on the platform.
Unique therapeutic mechanism,
The new hypoglycemic drugs highlight a new breakthrough in T2D research
S.
Food and Drug Administration (FDA) for the treatment
of T2D 。 Tirzepatide is a single molecule that binds and activates both GIP receptors and GLP-1 receptors, both of which belong to incretinin and play an important role
in glucose and energy metabolism.
In addition to promoting insulin secretion, GLP-1 also has the effect of inhibiting glucagon secretion, but this inhibition is absent
in hypoglycemia.
In addition, GLP-1 can also slow gastric emptying, promote satiety, and reduce food intake [2].
At the same time, GIP has been shown to promote insulin secretion in a glucose-dependent manner and, in the physiological state, has been shown to have a stronger insulin secretion effect than GLP-1 [3,4].
As a new hypoglycemic drug, Tirzepatide has both GIP and GLP-1 receptor agonism, and has obvious advantages for the control of blood glucose and weight in T2D patients [5-9].
Professor Tong Nanwei further explained: "Previous SURPASS series clinical trials [5-9] have evaluated the efficacy and safety of Tirzepatide (5mg, 10mg and 15mg) as a monotherapy and a representative class of hypoglycemic drugs in combination with T2D
。 Active comparators in the study included semeglutide injection 1 mg, insulin degludecine, and insulin
glargine.
Overall, data from five global registration clinical trials showed that Tirzepatide significantly reduced glycated hemoglobin (HbA1c) and body weight
in all three dose groups in T2D subjects with different diabetic courses.
"
From the data that have been reported, in the SURPASS-2 study comparing the efficacy and safety of Tirzepatide and semeglutide 1 mg in T2D patients with poor glycemic control after metformin treatment, at week 40, Tirzepatide 5 mg, 10 mg and 15 mg groups HbA1c Compared with the baseline change and the proportion of patients with HbA1c < 7%, ≤ 6.
5%, and <b24><</b24> 5.
7%, were better than those in the semeglutide 1 mg group
.
In the SURPASS-3 study, the change from baseline in the Tirzepatide 5mg, 10 mg, and 15 mg groups compared to baseline and the proportion of patients with HbA1c < 7%, ≤ 6.
5%, and <b25><</b25> 5.
7% were also better than titrated doses of insulin degludec at week 52
。 Professor Nanwei Tong concluded: "The data from the SURPASS series of studies show that Tirzepatide can bring significant hypoglycemic and weight-loss benefits
to T2D patients.
”
Taking into account the weight reduction and safety of blood sugar,
Post-mortem analysis provides new evidence
This year EASD disclosed a post-hoc analysis of a SURPASS-2 and SURPASS-3 study [1] designed to evaluate glycemic control goals (HbA 1c<7%/HbA) with Tirzepatide compared to semeglutide 1 mg and a titrated dose of degludecin in T2D patients</b10> and (≥) of (
- The median time to HbA1c<7.
0% at all doses of Tirzepatide was about 4 weeks faster than in the semeglutide 1 mg</b10> group (8.
1 versus 12 weeks) - The median time to HbA1c ≤6.
5% in all dose groups was 3.
6 weeks faster than the median time to semeglutide 1 mg (12.
1 versus 15.
7 weeks) and 3.
6 weeks faster than the titrated insulin degludec group (12.
1 versus 24.
1 weeks).
The median time to the table was almost 12 weeks
.
- Weight loss was ≥5% faster in the Tirzepatide 10 mg and 15 mg groups and 8 weeks
faster in the Tirzepatide 5 mg group compared to the semeglutide 1 mg group.
(Table).
Note: TZP, Tirzepatide; HR, risk ratio
.
- In terms of safety, in the SURPASS-2 study, hypoglycemia (blood glucose < 3 mmol/l or severe hypoglycemia)</b15> the ( the incidence of hypoglycemia in the Tirzepatide group (
"Combined with the data characteristics of the study, from the aspect of lowering glucose, we can find that some existing treatment options, such as long-acting insulin therapy, cannot achieve glycemic control goals within 3 months, while Tirzepatide can achieve it
.
" From the perspective of weight loss, Tirzepatide lost more than 5% of weight, which has actually achieved the effect of weight-loss drugs, and in T2D patients, Tirzepatide lost weight significantly faster than semeglutide 1mg
.
For the risk of hypoglycemia, which patients are concerned about, Tirzepatide also performs well
.
Professor Tong Nanwei explained
.
Recommended by authoritative guides,
Multiple expectations for the clinical application of hypoglycemic nova
UKPDS [10] has found that glycemic control is important in the metabolic management of diabetes, finding that every 1% decrease in HbA1c reduces the risk of all diabetes-related endpoints and diabetes-related death by 21% (P<0.
01)</b11>
Tong Nanwei
Chief physician, professor, doctoral supervisor
- Director of Department of Endocrinology and Metabolism, West China Hospital, Sichuan University
- Director of the Diabetes and Metabolism Research Center, West China Hospital, Sichuan University
- Vice Chairman of the Endocrinology Branch of the 9th Chinese Medical Association
- Member of the Standing Committee of the Endocrinologist Branch of the Chinese Medical Doctor Association
- Expert of the Endocrinology and Metabolism Professional Group of the Expert Committee on Rational Use of Drugs of the National Health and Family Planning Commission
- Chairman of the Endocrinology and Diabetes Committee of Sichuan Medical Association
- President of the Endocrinology and Metabolism Physician Branch of Sichuan Medical Association
- Academic and technical leader of Sichuan Province
- Chief expert of endocrine and metabolic diseases of Sichuan Provincial Health and Family Planning Commission
- Expert of the medical malpractice appraisal expert database of the Chinese Medical Association
- Associate Editor-in-Chief of Chinese Journal of Endocrinology and Metabolism
- Vice Chairman of the Editorial Board of Chinese Journal of Clinicians
References:
[1] EASD 2022.
591-SO-Patients with type 2 diabetes reach glycaemic targets faster with tirzepatide compared to semaglutide and titrated insulin degludec.
[2] Drucker DJ,Nauck MA.
Lancet.
2006; 368(9548):1696–1705.
[3] Gasbjerg LS,et al.
Diabetes.
2019; 68(5):906–917.
[4] Min T,et al.
Diabetes Ther.
2021 Jan; 12(1):143-157.
[5] Rosenstock J,et al.
Lancet.
2021; 398(10295):143-155.
[6] Frías JP,et al.
N Engl J Med.
2021; 385(6):503-515.
[7] Ludvik B,et al.
Lancet.
2021; 398(10300):583-598.
[8] Del Prato S,et al.
Lancet.
2021; 398(10313):1811-1824.
[9] Dahl D,et al.
JAMA.
2022; 327(6):534-545.
[10] Stratton IM,et al.
BMJ,2000,321(7258):405-412.
[11] Davies,M.
J.
,et al.
Diabetologia.
2022 Sep 24:1–42.
[12] Zhang F,et al.
J Evid Based Med.
2022 Jun 18.
"This article is only used to provide scientific information to medical and health professionals, and does not represent the position of the platform" Submission/reprint/business cooperation, please contact: pengsanmei@yxj.
org.
cn
